# Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

> **NCT00437294** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 86 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** placebo
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00437294
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437294, "Enzastaurin in Combination of Capecitabine to Treat Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00437294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*